Molecular Diagnostics

Sherlock Biosciences acquires Sense Biodetection to drive CRISPR-based test adoption

The acquisition enables Sherlock to combine its CRISPR, synthetic biology, and artificial intelligence technologies with Sense's instrument-free diagnostic hardware and rapid molecular amplification chemistries.

February 1, 2023

Widespread resistance to last-resort antibiotic spurs development of new assay

Scientists in Germany are developing an assay to detect resistance levels and thereby reduce the frequency of therapeutic failures when using colistin to treat infections with Enterobacter.

January 30, 2023

VieCure, Labcorp collaborate on clinical workflows, genomic testing

The firms are aiming to assist patient-specific treatment plans by integrating Labcorp’s precision medicine testing with VieCure’s clinical decision-support tool.

January 25, 2023

Geneseeq nabs CE Marks for minimal residual disease, early cancer detection tests

The firm has received CE Marks for liquid biopsy multicancer minimal residual disease detection and multicancer early detection kits to detect patients with solid tumors.

January 24, 2023

AI tool makes speedy gene-editing possible, offers alternative to CRISPR

An artificial intelligence program may enable the first simple production of customizable proteins called zinc fingers to treat diseases by turning genes on and off.

January 26, 2023

Geneoscopy applies for FDA approval of at-home CRC screening test

The premarket approval submission is based on results from a pivotal clinical trial in which Geneoscopy's test showed 94% sensitivity in detecting colorectal cancer and 45% sensitivity in detecting advanced adenomas.

January 24, 2023

Most Popular

Quest Diagnostics Q4 revenues down 15% on COVID testing but base business grew

In pilot study, liquid biopsy test differentiates between localized and metastatic cancer to inform tailored treatment

SD Biosensor, SJL Partners complete acquisition of Meridian Bioscience

Roche reports flat diagnostics revenue growth for 2022

French point-of-care testing firm Biosynex to acquire Chembio Diagnostics for $17.2M

OIG report outlines challenges with CDC-supported COVID-19 vaccination programs

Thermo Fisher Scientific, AstraZeneca to develop solid tissue and blood-based CDx for NSCLC

The companion diagnostic leverages Thermo Fisher’s Oncomine Dx Express Test on its Genexus Dx System, a fully integrated next-generation sequencing platform, with an automated specimen-to-report workflow that provides results in 24 hours.

January 24, 2023

Thermo Fisher Scientific launches sequencing assay to ID variants that may resist HIV therapies

The assay, which uses HIV RNA extracted from plasma or dried blood spots, is designed to analyze genomic mutations in the protease, reverse transcriptase, and integrase regions of the HIV-1 pol gene across nine subtypes of global significance.

January 24, 2023

Qiagen Digital Insights launches NGS analysis to process whole genome for $1 in cloud computing costs

The product incorporates a software accelerator that quickly converts raw sequencing data in FASTQ files from any paired-end short-read sequencing platform into interpretable lists of genetic variants in the VCF format.

January 23, 2023

DNA sequencing method offers peek into genomic black box

University of Cambridge researchers have outlined a new DNA sequencing method that detects where and how small molecule drugs interact with a targeted genome.

January 23, 2023

Agilent, Quest extend access to NGS liquid biopsy CDx for NSCLC

The agreement between Agilent and Quest aims to enable broader adoption of ctDx First, a single-site premarket approved test performed at the Resolution Bioscience CLIA-certified laboratory in Kirkland, WA.

January 23, 2023

Qiagen launches molecular diagnostic platform for automated sample processing

The EZ2 Connect MDx uses a high level of automation to enable labs to purify DNA and RNA from 24 samples in parallel in 30 minutes.

January 18, 2023

Page 1 of 170

Next Page